These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Static all-atom energetic mappings of the SARS-Cov-2 spike protein and dynamic stability analysis of "Up" versus "Down" protomer states. Peters MH; Bastidas O; Kokron DS; Henze CE PLoS One; 2020; 15(11):e0241168. PubMed ID: 33170884 [TBL] [Abstract][Full Text] [Related]
3. Static All-Atom Energetic Mappings of the SARS-Cov-2 Spike Protein with Potential Latch Identification of the Down State Protomer. Peters MH; Bastidas O; Kokron DS; Henze C bioRxiv; 2020 Jun; ():. PubMed ID: 32511362 [TBL] [Abstract][Full Text] [Related]
4. Transformations, Lineage Comparisons, and Analysis of Down-to-Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein, Including the UK Variant B.1.1.7. Peters MH; Bastidas O; Kokron DS; Henze CE Microbiol Spectr; 2021 Sep; 9(1):e0003021. PubMed ID: 34346753 [TBL] [Abstract][Full Text] [Related]
5. Site Density Functional Theory and Structural Bioinformatics Analysis of the SARS-CoV Spike Protein and hACE2 Complex. Kumawat N; Tucs A; Bera S; Chuev GN; Valiev M; Fedotova MV; Kruchinin SE; Tsuda K; Sljoka A; Chakraborty A Molecules; 2022 Jan; 27(3):. PubMed ID: 35164065 [TBL] [Abstract][Full Text] [Related]
6. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain. Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V F1000Res; 2020; 9():576. PubMed ID: 32802318 [No Abstract] [Full Text] [Related]
8. Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor. Lata S; Akif M J Cell Biochem; 2022 Jul; 123(7):1207-1221. PubMed ID: 35620980 [TBL] [Abstract][Full Text] [Related]
9. Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2. Celik I; Khan A; Dwivany FM; Fatimawali ; Wei DQ; Tallei TE Mol Divers; 2022 Dec; 26(6):3309-3324. PubMed ID: 35138508 [TBL] [Abstract][Full Text] [Related]
10. Computational screening of 645 antiviral peptides against the receptor-binding domain of the spike protein in SARS-CoV-2. Sakib MMH; Nishat AA; Islam MT; Raihan Uddin MA; Iqbal MS; Bin Hossen FF; Ahmed MI; Bashir MS; Hossain T; Tohura US; Saif SI; Jui NR; Alam M; Islam MA; Hasan MM; Sufian MA; Ali MA; Islam R; Hossain MA; Halim MA Comput Biol Med; 2021 Sep; 136():104759. PubMed ID: 34403938 [TBL] [Abstract][Full Text] [Related]
11. Molecular insights into the binding variance of the SARS-CoV-2 spike with human, cat and dog ACE2 proteins. Zang Y; Li X; Zhao Y; Wang H; Hao D; Zhang L; Yang Z; Yuan X; Zhang S Phys Chem Chem Phys; 2021 Jun; 23(24):13752-13759. PubMed ID: 34132301 [TBL] [Abstract][Full Text] [Related]
12. Investigation of potential inhibitor properties of violacein against HIV-1 RT and CoV-2 Spike RBD:ACE-2. Dogancı MA; Ay Sal F; Guler HI; Katı H; Ceylan E; Belduz AO; Bozdal G; Yaylı N; Canakcı S World J Microbiol Biotechnol; 2022 Jul; 38(9):161. PubMed ID: 35834025 [TBL] [Abstract][Full Text] [Related]
13. Highly conserved binding region of ACE2 as a receptor for SARS-CoV-2 between humans and mammals. Hayashi T; Abiko K; Mandai M; Yaegashi N; Konishi I Vet Q; 2020 Dec; 40(1):243-249. PubMed ID: 32921279 [TBL] [Abstract][Full Text] [Related]
14. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
15. Structural and simulation analysis of hotspot residues interactions of SARS-CoV 2 with human ACE2 receptor. Veeramachaneni GK; Thunuguntla VBSC; Bobbillapati J; Bondili JS J Biomol Struct Dyn; 2021 Jul; 39(11):4015-4025. PubMed ID: 32448098 [TBL] [Abstract][Full Text] [Related]
16. A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2. Wang X; Yang C; Sun Y; Sui X; Zhu T; Wang Q; Wang S; Yang J; Yang W; Liu F; Zhang M; Wang Y; Luo Y Environ Int; 2021 Feb; 147():106361. PubMed ID: 33401173 [TBL] [Abstract][Full Text] [Related]
18. [Peptide inhibitors of the interaction of the SARS-CoV-2 receptor-binding domain with the ACE2 cell receptor]. Bibilashvili RS; Sidorova MV; Dudkina US; Palkeeva ME; Molokoedov AS; Kozlovskaya LI; Egorov AM; Ishmukhametov AA; Parfyonova YV Biomed Khim; 2021 May; 67(3):244-250. PubMed ID: 34142531 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of molecular interaction, physicochemical parameters and conserved pattern of SARS-CoV-2 Spike RBD and hACE2: in silico and molecular dynamics approach. Chakraborty C; Sharma AR; Mallick B; Bhattacharya M; Sharma G; Lee SS Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1708-1723. PubMed ID: 33629340 [TBL] [Abstract][Full Text] [Related]
20. Atomistic insight into the essential binding event of ACE2-derived peptides to the SARS-CoV-2 spike protein. Sarto C; Florez-Rueda S; Arrar M; Hackenberger CPR; Lauster D; Di Lella S Biol Chem; 2022 Apr; 403(5-6):615-624. PubMed ID: 35357791 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]